Sarepta Therapeutics Inc Quick Ratio (SRPT) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sarepta Therapeutics Inc   (NASDAQ: SRPT)

Sarepta Therapeutics Inc 's Quick Ratio

SRPT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.57 below Sarepta Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 316 other companies have achieved higher Quick Ratio than Sarepta Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1555, from total ranking in the first quarter 2026 at 2029.

Explain Quick Ratio?
How much Cash & cash equivalents SRPT´s has?
What are SRPT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SRPT Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -4.12 % -31.67 % 9.18 % -23.85 % -7.4 %
Y / Y Cash & cash equivalent Change -1.46 % 24.95 % -30.64 % -28.99 % -45.21 %
Quick Ratio MRQ 1.57 1.7 1.43 1.95 1.53
SRPT's Total Ranking # 1555 # 2029 # 1586 # 1868 # 2450
Seq. Current Liabilities Change 31.26 % -41.65 % 50.62 % -16.88 % -6.46 %
Seq. Cash & cash equivalent Change 20.71 % -30.49 % 10.42 % 6.36 % 53.06 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 317
Healthcare Sector # 557
Overall Market # 1604


Quick Ratio Statistics
High Average Low
13.7 5.31 0.93
(Dec 31 2012)   (Mar 31 2025)




Financial Statements
Sarepta Therapeutics Inc 's Current Liabilities $ 503 Millions Visit SRPT's Balance sheet
Sarepta Therapeutics Inc 's Cash & cash equivalent $ 788 Millions Visit SRPT's Balance sheet
Source of SRPT's Sales Visit SRPT's Sales by Geography


Cumulative Sarepta Therapeutics Inc 's Quick Ratio

SRPT's Quick Ratio for the trailling 12 Months

SRPT Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -12.42 % -13.07 % -2.65 % -9.84 % 2.22 %
Y / Y Cash & cash equivalent TTM Growth -16.61 % -28.49 % -42.39 % -38.37 % -38.09 %
Quick Ratio TTM 1.63 1.62 1.43 1.66 1.72
Total Ranking TTM # 1650 # 2069 # 1342 # 1465 # 1471
Seq. Current Liabilities TTM Growth -1.08 % -8.15 % 2.6 % -6.04 % -1.82 %
Seq. Cash & cash equivalent TTM Growth -0.36 % 4.19 % -11.76 % -8.96 % -14.56 %

Quick ratio ranking by company, industry and sector >> Back to SRPT Financial Strength Comparisons >> Go to Compare SRPT Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Sarepta Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Sarepta Therapeutics Inc 's Quick Ratio to 1.63, Quick Ratio remained below SRPT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 437 other companies have achieved higher Quick Ratio than Sarepta Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3156.

Explain Quick Ratio?
How much Cash & cash equivalents SRPT´s has?
What are SRPT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 438
Healthcare Sector # 898
Within the Market # 1555


trailing twelve months Quick Ratio Statistics
High Average Low
6.16 2.69 0.54
(Jun 30 2018)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Biohaven Ltd   4.28 $ 267.866  Millions$ 62.658  Millions
Incannex Healthcare Inc  4.25 $ 67.711  Millions$ 15.940  Millions
Longeveron Inc   4.20 $ 18.104  Millions$ 4.307  Millions
Vistagen Therapeutics Inc   4.15 $ 46.439  Millions$ 11.192  Millions
Gyre Therapeutics Inc   4.12 $ 86.289  Millions$ 20.957  Millions
Seaport Therapeutics Inc   4.11 $ 64.423  Millions$ 15.674  Millions
Prelude Therapeutics Inc  3.99 $ 151.757  Millions$ 38.042  Millions
Alx Oncology Holdings Inc  3.97 $ 22.753  Millions$ 5.731  Millions
Actinium Pharmaceuticals Inc  3.94 $ 36.473  Millions$ 9.260  Millions
Veru Inc   3.88 $ 23.880  Millions$ 6.156  Millions
Gain Therapeutics inc  3.81 $ 13.084  Millions$ 3.434  Millions
Bolt Biotherapeutics Inc   3.79 $ 29.823  Millions$ 7.867  Millions
Acurx Pharmaceuticals inc   3.72 $ 10.656  Millions$ 2.865  Millions
Maplight Therapeutics Inc   3.71 $ 71.633  Millions$ 19.294  Millions
Aptevo Therapeutics Inc   3.47 $ 17.997  Millions$ 5.188  Millions
Ataibeckley Inc   3.43 $ 168.807  Millions$ 49.221  Millions
Dogwood Therapeutics inc   3.40 $ 9.628  Millions$ 2.831  Millions
Tvardi Therapeutics Inc   3.39 $ 30.865  Millions$ 9.113  Millions
Biomea Fusion Inc   3.32 $ 34.824  Millions$ 10.483  Millions
Abeona Therapeutics Inc   3.32 $ 146.826  Millions$ 44.233  Millions
Foghorn Therapeutics Inc   3.31 $ 167.582  Millions$ 50.579  Millions
Cingulate Inc   3.29 $ 28.403  Millions$ 8.631  Millions
Unicycive Therapeutics Inc  3.28 $ 61.425  Millions$ 18.704  Millions
Harmony Biosciences Holdings inc   3.17 $ 667.791  Millions$ 210.812  Millions
Pulmatrix Inc   3.15 $ 2.168  Millions$ 0.689  Millions
Nextcure Inc   3.13 $ 20.088  Millions$ 6.413  Millions
Dianthus Therapeutics Inc   3.13 $ 107.611  Millions$ 34.389  Millions
Tg Therapeutics Inc   3.02 $ 811.665  Millions$ 268.493  Millions
Dermata Therapeutics Inc   3.02 $ 4.413  Millions$ 1.462  Millions
Xilio Therapeutics Inc   2.99 $ 136.040  Millions$ 45.487  Millions

Date modified: 2026-09-11T09:41:36+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.